{
  "documentMetadata": {
    "title": "Amnionitis, Chorioamnionitis, Septic Abortion",
    "lastUpdated": "2025-01-07",
    "sourceFile": "Amnionitis, Chorioamnionitis, Septic Abortion.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Amnionitis, septic abortion.",
        "Indication for dilation and curettage (D & C) of uterus.",
        "Culture amniotic fluid and blood; hopefully culture results will allow early switch from empiric to specific (directed) therapy.",
        "Some use NAATs to screen for the presence of C. trachomatis and/or N. gonorrhoeae.",
        "Ureaplasma sp./Mycoplasma sp. may be pathogenic but not detected with routine culture.",
        "Chorioamnionitis (Intraamniotic infection)",
        "Based on clinical findings alone.",
        "There are no controlled randomized treatment trials. Following recommendations are based on known in vitro susceptibilities of frequent pathogens, observational data, and expert opinions:",
        "As such, our opinions may differ from that of the American College of Obstetrics and Gynecology (Obst & Gyn 2017;130: 490)",
        "Pertinent refs: Cochrane Database of Systematic Reviews (12) CD010976, 2014 Dec.19.; Review: Frontiers in Pharmacol 2017;8:97(PMID:28352229)"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Bacteroides sp., especially Prevotella bivia",
        "Streptococcus sp. (Groups A, B)",
        "Enterobacteriaceae",
        "Chlamydia trachomatis",
        "Ureaplasma urealyticum (less common)",
        "Mycoplasma sp"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV",
            "frequency": "q8h",
            "notes": "over 4 hr, see drug page for comment on loading dose"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "If critically ill",
        "components": [
          {
            "drug": "Meropenem",
            "dose": "1-2 gm",
            "route": "IV",
            "notes": "loading dose, then 0.5-1 gm IV q8h"
          }
        ]
      }
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Other potential empiric regimens:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Doripenem",
                "dose": "500 mg",
                "route": "IV",
                "frequency": "q8h",
                "connector": "or"
              },
              {
                "drug": "Imipenem",
                "dose": "0.5 gm",
                "route": "IV",
                "frequency": "q6h",
                "connector": "or"
              },
              {
                "drug": "Ertapenem",
                "dose": "1 gm",
                "route": "IV",
                "frequency": "q24h"
              }
            ],
            "notes": "NAI"
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Ampicillin-sulbactam",
                "dose": "3 gm",
                "route": "IV",
                "frequency": "q6h"
              }
            ],
            "notes": "up to 50% of E.coli are now resistant in some locations"
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Clindamycin",
                "dose": "900 mg",
                "route": "IV",
                "frequency": "q8h",
                "connector": "+"
              },
              {
                "drug": "Ceftriaxone",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q24h"
              }
            ],
            "notes": "NOTE: one-third of Group B streptococci are resistant to Clindamycin"
          }
        },
        {
          "type": "paragraph",
          "text": "If NAAT is positive for C. trachomatis, Ureaplasma, or Mycoplasma, add Doxycycline 100 mg IV q12h"
        },
        {
          "type": "paragraph",
          "text": "After discharge: Doxycycline or continue Clindamycin for C. trachomatis."
        }
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "None"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "IV Clindamycin is effective for C. trachomatis, but not sure about efficacy of doses used orally.",
        "See Comment regarding avoidance of Ampicillin + Gentamicin + Clindamycin"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "American College of Obstetricians and Gynecologists (Obst & Gyn 2017;130:490) opinion summary of suggested management of amnionitis with ampicillin + gentamicin + clindamycin",
        "We are concerned by the ever increasing resistance of Enterobacteriaceae to early-generation beta lactams and aminoglycosides",
        "Avoidance, if possible, of the inherent risk of nephrotoxicity and ototoxicity with the use of aminoglycosides",
        "Increasing resistance of anaerobic gram negative pathogens to clindamycin",
        "Absence of any controlled comparative clinical trials of various treatment regimens",
        "In septic abortion, C. perfringens may cause fulminant intravascular hemolysis.",
        "In postpartum patients with enigmatic fever and/or pulmonary emboli, consider septic pelvic vein thrombophlebitis.",
        "NAI = not an FDA-approved indication."
      ]
    }
  ]
}